The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)
Sandra Gottschling(Heidelberg University), Roland Penzel(Heidelberg University), Michael Meister(German Center for Lung Research), Helge Bischoff(Heidelberg University), David F. Heigener(Agaplesion Diakonieklinikum Rotenburg), Thomas Kuhnt(Leipzig University), Wilfried Eberhardt(National Center for Tumor Diseases), Jürgen R. Fischer, Esther Herpel(Memorial Sloan Kettering Cancer Center), Thomas Muley(German Center for Lung Research), Michael Thomas, Peter Klein(Argonne National Laboratory), C. Kortsik, Ines Moldenhauer(AstraZeneca (United Kingdom)), Claus‐Henning Köhne(Klinikum Oldenburg), Philipp A. Schnabel(Heidelberg University)
Cited by 13
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study
|PLoS Medicine|2019|1.1k